Los Angeles Capital Management LLC Acquires 21,673 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Los Angeles Capital Management LLC lifted its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 236.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,827 shares of the company’s stock after acquiring an additional 21,673 shares during the quarter. Los Angeles Capital Management LLC owned 0.05% of Protagonist Therapeutics worth $892,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its holdings in shares of Protagonist Therapeutics by 353.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,675 shares of the company’s stock valued at $153,000 after acquiring an additional 5,202 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Protagonist Therapeutics by 11.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,338 shares of the company’s stock valued at $237,000 after purchasing an additional 1,093 shares during the last quarter. Birchview Capital LP grew its stake in Protagonist Therapeutics by 26.3% in the fourth quarter. Birchview Capital LP now owns 48,000 shares of the company’s stock valued at $1,101,000 after purchasing an additional 10,000 shares during the last quarter. Profund Advisors LLC grew its stake in Protagonist Therapeutics by 13.4% in the third quarter. Profund Advisors LLC now owns 58,716 shares of the company’s stock valued at $979,000 after purchasing an additional 6,933 shares during the last quarter. Finally, Federated Hermes Inc. grew its stake in Protagonist Therapeutics by 102.6% in the third quarter. Federated Hermes Inc. now owns 60,234 shares of the company’s stock valued at $1,005,000 after purchasing an additional 30,507 shares during the last quarter. 98.63% of the stock is currently owned by institutional investors.

Insider Transactions at Protagonist Therapeutics

In other news, CFO Asif Ali sold 1,234 shares of the company’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $25.11, for a total transaction of $30,985.74. Following the completion of the transaction, the chief financial officer now directly owns 37,163 shares of the company’s stock, valued at approximately $933,162.93. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, Director William D. Waddill sold 8,000 shares of the stock in a transaction on Friday, June 7th. The stock was sold at an average price of $35.00, for a total value of $280,000.00. Following the completion of the transaction, the director now directly owns 12,000 shares of the company’s stock, valued at approximately $420,000. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Asif Ali sold 1,234 shares of the stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $25.11, for a total value of $30,985.74. Following the completion of the transaction, the chief financial officer now directly owns 37,163 shares of the company’s stock, valued at $933,162.93. The disclosure for this sale can be found here. Insiders sold a total of 69,234 shares of company stock valued at $2,250,386 in the last three months. 5.40% of the stock is currently owned by company insiders.

Protagonist Therapeutics Price Performance

Shares of PTGX stock opened at $32.01 on Tuesday. The company has a market cap of $1.88 billion, a price-to-earnings ratio of 13.12 and a beta of 2.12. The stock has a 50 day simple moving average of $29.44 and a 200-day simple moving average of $27.38. Protagonist Therapeutics, Inc. has a 1-year low of $13.72 and a 1-year high of $35.96.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Tuesday, May 7th. The company reported $3.26 earnings per share for the quarter, topping the consensus estimate of $2.51 by $0.75. The business had revenue of $254.95 million for the quarter, compared to analyst estimates of $300.00 million. Analysts anticipate that Protagonist Therapeutics, Inc. will post 2.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have issued reports on PTGX shares. HC Wainwright reiterated a “buy” rating and issued a $38.00 target price on shares of Protagonist Therapeutics in a research note on Friday, June 14th. JPMorgan Chase & Co. upped their target price on Protagonist Therapeutics from $34.00 to $37.00 and gave the company an “overweight” rating in a research report on Wednesday, February 28th. JMP Securities reiterated a “market outperform” rating and issued a $45.00 target price on shares of Protagonist Therapeutics in a research report on Monday, June 17th. Finally, StockNews.com raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.